cholangiocarcinoma

ESMO: Relay spotlights expanded FGFR2 inhibitor data it hopes will pave accelerated approval
Fierce Biotech
Sun, 09/11/22 - 10:57 pm
ESMO
Relay Therapeutics
RLY-4008
cholangiocarcinoma
Incyte nabs 2nd ever approval ahead of schedule as FDA insists it can still review on time
Endpoints
Mon, 04/20/20 - 10:58 am
Incyte
Pemazyre
pemigatinib
bile duct cancer
cholangiocarcinoma
FDA
FDA accepts Incyte’s NDA for priority review of pemigatinib to treat cholangiocarcinoma
Pharmaceutical Business Review
Fri, 11/29/19 - 02:24 pm
FDA
Incyte
priority review
pemigatinib
cholangiocarcinoma
Agios Pharma's Tibsovo Shows Positive Results in Phase III for Another Cancer Indication
BioSpace
Thu, 05/16/19 - 06:44 pm
Agios Pharmaceuticals
Tibsovo
ivosidenib
clinical trials
cholangiocarcinoma
RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round
CP Wire
Fri, 04/26/19 - 10:06 am
Sriaomics
STP705
cholangiocarcinoma
hepatocellular carcinoma
RNAi
RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round
Fri, 04/26/19 - 10:01 am
Sriaomics
STP705
cholangiocarcinoma
hepatocellular carcinoma
Imbrium Therapeutics and Mundipharma EDO Announce Orphan Drug Designation for Relapsed Refractory Biliary Tract Cancer Treatment
CP Wire
Fri, 02/22/19 - 10:00 am
Imbrium Therapeutics
Mundipharma EDO
Purdue Pharma
etoposide toniribate
cholangiocarcinoma
Imbrium Therapeutics and Mundipharma EDO Announce Orphan Drug Designation for Relapsed Refractory Biliary Tract Cancer Treatment
Fri, 02/22/19 - 09:59 am
Imbrium Therapeutics
Mundipharma EDO
Purdue Pharma
etoposide toniribate
cholangiocarcinoma